415 related articles for article (PubMed ID: 15572167)
1. Corticotropin-releasing hormone and urocortin: redundant or distinctive functions?
Gysling K; Forray MI; Haeger P; Daza C; Rojas R
Brain Res Brain Res Rev; 2004 Dec; 47(1-3):116-25. PubMed ID: 15572167
[TBL] [Abstract][Full Text] [Related]
2. Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress.
Bale TL; Contarino A; Smith GW; Chan R; Gold LH; Sawchenko PE; Koob GF; Vale WW; Lee KF
Nat Genet; 2000 Apr; 24(4):410-4. PubMed ID: 10742108
[TBL] [Abstract][Full Text] [Related]
3. Modulation of corticotropin-releasing hormone type 2 receptor and urocortin 1 and urocortin 2 mRNA expression in the cardiovascular system of prairie voles following acute or chronic stress.
Pournajafi-Nazarloo H; Partoo L; Sanzenbacher L; Azizi F; Carter CS
Neuroendocrinology; 2007; 86(1):17-25. PubMed ID: 17551267
[TBL] [Abstract][Full Text] [Related]
4. The powerful cardioprotective effects of urocortin and the corticotropin releasing hormone (CRH) family.
Davidson SM; Rybka AE; Townsend PA
Biochem Pharmacol; 2009 Jan; 77(2):141-50. PubMed ID: 18817752
[TBL] [Abstract][Full Text] [Related]
5. Limbic corticotropin-releasing hormone receptor 1 mediates anxiety-related behavior and hormonal adaptation to stress.
Müller MB; Zimmermann S; Sillaber I; Hagemeyer TP; Deussing JM; Timpl P; Kormann MS; Droste SK; Kühn R; Reul JM; Holsboer F; Wurst W
Nat Neurosci; 2003 Oct; 6(10):1100-7. PubMed ID: 12973355
[TBL] [Abstract][Full Text] [Related]
6. Corticotropin-releasing hormone skin signaling is receptor-mediated and is predominant in the sebaceous glands.
Krause K; Schnitger A; Fimmel S; Glass E; Zouboulis CC
Horm Metab Res; 2007 Feb; 39(2):166-70. PubMed ID: 17326013
[TBL] [Abstract][Full Text] [Related]
7. Neuropeptide urocortin 1 and its receptors are expressed in the human liver.
Simopoulos C; Christodoulou E; Lambropoulou M; Tsaroucha AK; Kakolyris S; Polychronidis A; Karayiannakis AJ; Chatzaki E
Neuroendocrinology; 2009; 89(3):315-26. PubMed ID: 19096201
[TBL] [Abstract][Full Text] [Related]
8. Expression of type 1 corticotropin-releasing hormone (CRH) receptor mRNA in the hypothalamic paraventricular nucleus following restraint stress in CRH-deficient mice.
Makino S; Tanaka Y; Nazarloo HP; Noguchi T; Nishimura K; Hashimoto K
Brain Res; 2005 Jun; 1048(1-2):131-7. PubMed ID: 15919058
[TBL] [Abstract][Full Text] [Related]
9. Neuropeptide urocortin and its receptors are expressed in rat Kupffer cells.
Charalampopoulos I; Androulidaki A; Minas V; Chatzaki E; Tsatsanis C; Notas G; Xidakis C; Kolios G; Kouroumalis E; Margioris AN; Gravanis A
Neuroendocrinology; 2006; 84(1):49-57. PubMed ID: 17090973
[TBL] [Abstract][Full Text] [Related]
10. Potent mast cell degranulation and vascular permeability triggered by urocortin through activation of corticotropin-releasing hormone receptors.
Singh LK; Boucher W; Pang X; Letourneau R; Seretakis D; Green M; Theoharides TC
J Pharmacol Exp Ther; 1999 Mar; 288(3):1349-56. PubMed ID: 10027877
[TBL] [Abstract][Full Text] [Related]
11. Modulation of corticotropin-releasing hormone receptor type 2 mRNA expression by CRH deficiency or stress in the mouse heart.
Pournajafi Nazarloo H; Tanaka Y; Dorobantu M; Hashimoto K
Regul Pept; 2003 Sep; 115(2):131-8. PubMed ID: 12972328
[TBL] [Abstract][Full Text] [Related]
12. The type 2 corticotrophin-releasing hormone receptor mediates orexin A-induced luteinising hormone suppression in ovariectomised rats.
Iwasa T; Matsuzaki T; Kiyokawa M; Shimizu F; Minakuchi M; Kuwahara A; Maegawa M; Yasui T; Irahara M
J Neuroendocrinol; 2007 Sep; 19(9):732-8. PubMed ID: 17680889
[TBL] [Abstract][Full Text] [Related]
13. Animal models of CRH deficiency.
Venihaki M; Majzoub JA
Front Neuroendocrinol; 1999 Apr; 20(2):122-45. PubMed ID: 10328987
[TBL] [Abstract][Full Text] [Related]
14. Urocortin II is expressed in human pregnant myometrial cells and regulates myosin light chain phosphorylation: potential role of the type-2 corticotropin-releasing hormone receptor in the control of myometrial contractility.
Karteris E; Hillhouse EW; Grammatopoulos D
Endocrinology; 2004 Feb; 145(2):890-900. PubMed ID: 14592950
[TBL] [Abstract][Full Text] [Related]
15. Urocortin, but not corticotropin-releasing hormone (CRH), activates the mitogen-activated protein kinase signal transduction pathway in human pregnant myometrium: an effect mediated via R1alpha and R2beta CRH receptor subtypes and stimulation of Gq-proteins.
Grammatopoulos DK; Randeva HS; Levine MA; Katsanou ES; Hillhouse EW
Mol Endocrinol; 2000 Dec; 14(12):2076-91. PubMed ID: 11117536
[TBL] [Abstract][Full Text] [Related]
16. [cDNA cloning and analysis of tissue-specific gene expression of rat urocortin II].
Chae JI; Ju SK; Lee MK; Park JH; Yoon JH; Shim JH; Lee DS
Mol Biol (Mosk); 2009; 43(1):91-6. PubMed ID: 19334530
[TBL] [Abstract][Full Text] [Related]
17. Potential uses of corticotropin-releasing hormone antagonists.
Zoumakis E; Rice KC; Gold PW; Chrousos GP
Ann N Y Acad Sci; 2006 Nov; 1083():239-51. PubMed ID: 17148743
[TBL] [Abstract][Full Text] [Related]
18. Expression profiling identifies the CRH/CRH-R1 system as a modulator of neurovascular gene activity.
Deussing JM; Kühne C; Pütz B; Panhuysen M; Breu J; Stenzel-Poore MP; Holsboer F; Wurst W
J Cereb Blood Flow Metab; 2007 Aug; 27(8):1476-95. PubMed ID: 17293846
[TBL] [Abstract][Full Text] [Related]
19. Expression of urocortin and corticotropin-releasing hormone receptors in the bovine adrenal gland.
Squillacioti C; De Luca A; Liguori G; Paino S; Mirabella N
Gen Comp Endocrinol; 2011 Jul; 172(3):416-22. PubMed ID: 21504748
[TBL] [Abstract][Full Text] [Related]
20. Possible involvement of corticotropin-releasing factor receptor signaling on vascular inflammation.
Inada Y; Ikeda K; Tojo K; Sakamoto M; Takada Y; Tajima N
Peptides; 2009 Feb; 30(2):365-72. PubMed ID: 19026699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
